IBI310 + Sintilimab + Sorafenib
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Feb 7, 2021 → Dec 31, 2025
NCT ID
NCT04720716About IBI310 + Sintilimab + Sorafenib
IBI310 + Sintilimab + Sorafenib is a phase 3 stage product being developed by Innovent Biologics for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04720716. Target conditions include Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04720716 | Phase 3 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma